iShares Core MSCI AC Asia ex Japan Index ETF(03010.HK) rose by 1.96%, trading at HK$84.14 intraday
NewTimeSpace News: At 13:03 on April 27, 2026,iShares Core MSCI AC Asia ex Japan Index ETFETF (03010.HK) traded at HK$84.14, marking a 1.96% increase. It reached an intraday high of HK$84.32 and a low of HK$83.90. A total of 9,000 shares were traded, with a turnover of about HK$755,900. The ETF boasts assets under management of roughly HK$42.029 billion, with a net asset value per unit of HK$82.569 and a premium rate of -0.06%.
iShares Core MSCI AC Asia ex Japan Index ETF(03010.HK) tracks the MSCI AC Asia Ex-Japan Index. This index covers equities in major Asian markets including Chinese mainland, Hong Kong of China, Taiwan of China, South Korea, India and Singapore, fully reflecting the overall market performance of Asia excluding Japan.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment